Dexcom (DXCM) Common Equity (2010 - 2026)

Dexcom (DXCM) has 17 years of Common Equity data on file, last reported at $3.0 billion in Q1 2026.

• On a quarterly basis, Common Equity rose 30.46% year-over-year to $3.0 billion in Q1 2026; TTM through Mar 2026 was $3.0 billion, a 30.46% increase from a year earlier, with the FY2025 full-year figure at $400000.0, down 99.98% from the prior year.
• Common Equity for Q1 2026 stood at $3.0 billion, up from $400000.0 in the prior quarter.
• Over the last five years, Common Equity for DXCM reached as high as $3.0 billion in Q1 2026 and fell as low as $400000.0 in Q3 2025.
• Historically, Common Equity has averaged $2.0 billion across 5 years, with a median of $2.2 billion in 2022.
• Across the five-year window, Common Equity surged 33.1% in 2022 and plunged 99.98% in 2025, its largest moves.
• Year by year, Common Equity stood at $2.1 billion in 2022, then declined by 2.96% to $2.1 billion in 2023, then grew by 1.64% to $2.1 billion in 2024, then plunged by 99.98% to $400000.0 in 2025, then soared by 739125.0% to $3.0 billion in 2026.
• Per Business Quant data, the three most recent Common Equity figures were $3.0 billion in Q1 2026, $400000.0 in Q4 2025, and $400000.0 in Q3 2025.